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Inducing Proinflammatory Cytokines in Macrophages through a c-Jun
N-Terminal Kinase- and Toll-Like Receptor 4-Dependent
and Retinol-Independent Mechanism
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Retinol-binding protein 4 (RBP4), the sole retinol transporter in blood, is secreted from adipocytes and liver. Serum RBP4 levels
correlate highly with insulin resistance, other metabolic syndrome factors, and cardiovascular disease. Elevated serum RBP4
causes insulin resistance, but the molecular mechanisms are unknown. Here we show that RBP4 induces expression of proin-
flammatory cytokines in mouse and humanmacrophages and thereby indirectly inhibits insulin signaling in cocultured adi-
pocytes. This occurs through activation of c-Jun N-terminal protein kinase (JNK) and Toll-like receptor 4 (TLR4) pathways inde-
pendent of the RBP4 receptor, STRA6. RBP4 effects are markedly attenuated in JNK1/ JNK2/macrophages and TLR4/
macrophages. Because RBP4 is a retinol-binding protein, we investigated whether these effects are retinol dependent. Unexpect-
edly, retinol-free RBP4 (apo-RBP4) is as potent as retinol-bound RBP4 (holo-RBP4) in inducing proinflammatory cytokines in
macrophages. Apo-RBP4 is likely to be physiologically significant since RBP4/retinol ratios are increased in serum of lean and
obese insulin-resistant humans compared to ratios in insulin-sensitive humans, indicating that higher apo-RBP4 is associated
with insulin resistance independent of obesity. Thus, RBP4may cause insulin resistance by contributing to the development of
an inflammatory state in adipose tissue through activation of proinflammatory cytokines in macrophages. This process reveals a
novel JNK- and TLR4-dependent and retinol- and STRA6-independent mechanism of action for RBP4.
Obesity is a major risk factor for insulin resistance, which is acritical pathogenic factor in type 2 diabetes (50). Determina-
tion of the physiologic and cellular mechanisms linking obesity to
type 2 diabetes could lead to development of new prevention and
treatment approaches. Multiple mechanisms may contribute, in-
cluding abnormal production of adipocyte-secreted proteins (adi-
pokines) (1, 15, 29), infiltration of white adipose tissue (WAT)
with proinflammatory macrophages (42), and aberrant lipid de-
position in tissues such as muscle and liver (51). These mecha-
nisms are not mutually exclusive. For example, adipokines can
affect inflammation and lipid deposition in tissues (15).
Serum retinol-binding protein 4 (RBP4) is an adipokine and is
also secreted by liver. RBP4 levels are increased in obese and insu-
lin-resistant humans and mouse models, and genetic or pharma-
cologic elevation of serum RBP4 causes insulin resistance in nor-
mal mice (19, 31, 65). Although many studies show strong
correlations of serum RBP4 levels with obesity and the severity of
insulin resistance (9, 16, 27, 35), others do not (8, 17, 32, 46), as
reviewed in reference 32. This may result from the use of different
populations of human subjects or from methodological issues
with RBP4 assays (18, 32, 64). Many studies also show that serum
RBP4 levels correlate with other components of the metabolic
syndrome in humans, including hypertension (47, 54, 64), dyslip-
idemia (41, 47, 64, 67), waist/hip ratio (31, 47, 64), cardiovascular
disease (26), and intra-abdominal fat mass (9, 31, 36, 56). Strong
associations have been demonstrated in large-scale population
studies in several ethnic backgrounds (38, 47). In addition, genetic
studies support a potential role for RBP4 in causing insulin resis-
tance in humans. A study in approximately 6,500 aging adults
showed that a gain-of-function single nucleotide polymorphism
(SNP) in the RBP4 promoter is associated with a 2-fold-increased
risk of type 2 diabetes (58). This SNP increases RBP4 promoter
activity and is positively associated with RBP4 expression in adi-
pose tissue and with body mass index (BMI) (40).
While elevation of serumRBP4 levels is sufficient to cause insulin
resistance in mice (45, 65, 68), the molecular mechanism is not un-
derstood. Insulin signaling is impaired in skeletalmuscle ofmicewith
transgenic or pharmacologic elevation of RBP4, whereas insulin sig-
naling is increased inmicewith genetic or pharmacologic loweringof
RBP4 (65, 68). In addition, RBP4 treatment increases phosphoenol-
pyruvate carboxykinase (PEPCK)expressionandglucoseproduction
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in hepatoma cells (65) and PEPCK expression is elevated in the livers
of RBP4-injected mice (65). Incubation of isolated adipocytes with
RBP4 reduces the sensitivity to insulin-stimulated extracellular sig-
nal-regulated kinase (ERK) phosphorylation (43). These data pro-
vide some mechanistic insights into RBP4-mediated insulin resis-
tance, but the underlying cellular mechanisms are not known.
Obesity is a state of chronic, low-grade inflammation, and
macrophages are thought to play an important role in maintain-
ing this state in adipose tissue (42, 61, 63). Many molecules se-
creted by adipose tissue promote adipose tissue inflammation (33,
49, 53). Emerging evidence suggests a possible role for proinflam-
matory pathways in RBP4-induced insulin resistance. RBP4 ex-
pression in adipose tissue (66) and serumRBP4 levels (3) strongly
correlate with subclinical inflammation, including serum levels
(3) and adipose tissue expression (66) of proinflammatory cyto-
kines. Lifestyle intervention can reduce serum RBP4 levels in par-
allel with improvement in markers for subclinical inflammation
(3, 22). At the cellular level, a recent study showed that RBP4
stimulates cytokine secretion frommouse macrophages (11). An-
other study showed that the RBP4/retinol complex stimulates
JAK2/STAT5 signaling and expression of suppressor of cytokine
signaling 3 (SOCS3) (4), which has been implicated in insulin
resistance (34, 52). Together, these studies support the notion that
RBP4-induced insulin resistancemay involve inflammatory path-
ways.
It is not known whether RBP4’s effects on insulin action are
retinol (vitamin A) dependent. RBP4 delivers retinol to target tis-
sues, where it is metabolized to retinoic acid. Retinoids havemany
fundamental effects on cellular function, including gene tran-
scription (37), differentiation, proliferation (20), and immune
function (44). Retinol deficiency, which is accompanied by low
RBP4 levels, results in impaired immunity (60). The majority of
RBP4 in serum is retinol bound (holo-RBP4), although a small
amount is not bound to retinol (apo-RBP4). While the contribu-
tion of each form to insulin resistance is unknown, the proportion
of serum RBP4 that is apo-RBP4 is increased in obese people (39)
and the ratio of RBP4 to retinol is increased in people with type 2
diabetes (12).
Determination of the role of retinol in the effects of RBP4 on
insulin resistance is critical for discerning the mechanisms of
RBP4 action. Here we show that RBP4 can act independently of
retinol to impair insulin signaling in adipocytes indirectly, by in-
ducing proinflammatory cytokine production from macro-
phages. This is mediated, in part, by the Toll-like receptor 4
(TLR4) cell surface receptor and not by the RBP4 receptor,
STRA6, and involves the c-Jun N-terminal protein kinase (JNK)
signaling pathway. These studies enhance our understanding of
the mechanisms involved in RBP4-induced insulin resistance and
establish that RBP4, independent of retinol, has important bio-
logic effects.
MATERIALS AND METHODS
Recombinant RBP4 preparation and treatment.Mouse and human ret-
inol-bound RBP4 (holo-RBP4) was expressed in Escherichia coli and pu-
rified as described previously (65). The endotoxin level of this recombi-
nant protein was less than 0.001 endotoxin unit perg, which is the same
as the ambient endotoxin levels in reverse-osmosis double-deionized wa-
ter as quantitatively measured by the Limulus amoebocyte lysate test
(Lonza Limulus amoebocyte lysate QCL-1000; catalog no. 50-647 U). To
generate retinol-free (apo-RBP4) or retinol-reconstituted (add-back)
RBP4, holo-RBP4was first incubatedwith 40%butanol–60%diisopropyl
ether at 30°C overnight to remove retinol and centrifuged at 5,000 rpm for
5min, and the bottomphase containing recombinant RBP4was collected.
This step was repeated twice more with 1-h incubations of 40% butanol–
60% diisopropyl ether. The resulting retinol-stripped RBP4 (apo-RBP4)
was then incubated at 30°C overnight with either 100 mM retinol in eth-
anol to generate add-back RBP4 or with an equal volume of ethanol to
generate apo-RBP4. The holo, apo, and add-back forms of RBP4 were
purified by high-performance liquid chromatography (HPLC), and both
the protein quality and the efficiency of retinol binding were measured by
Western blotting after separation by nondenaturing gel electrophoresis
and by fluorescent spectrometry. After HPLC purification, RBP4 was di-
alyzed against 1 phosphate-buffered saline (PBS) for 4 h using a Slide A
Lyzer dialysis cassette (Thermo Scientific, catalog no. 66370). The dialy-
sate buffer was used as a vehicle control in experiments where indicated.
The protein was stored at80°C and protected from exposure to light.
Culture and coculture of 3T3L1 adipocytes and RAW264.7 macro-
phages. 3T3L1 preadipocyte culture and differentiation were performed
as described previously (25). RAW264.7macrophages weremaintained in
Dulbecco’s modified Eagle’s medium (DMEM), which was free of retinol
and other retinoids and contained 10% fetal bovine serum (FBS) and
antibiotics. Incubations with RBP4 were done under serum-free condi-
tions, except for specific experiments to compare RBP4 effects with and
without serum. Coculture of 3T3L1 adipocytes and RAW264.7 macro-
phages was performed as described previously with slight modifications
(55). In the direct contact system, 3T3L1 adipocytes were cultured in a
6-well dish and 2 105 RAW264.7macrophageswere plated directly onto
3T3L1 adipocytes. Cells were cultured overnight prior to treatment with
RBP4, inhibitors, or antibodies. In the noncontact Transwell system,
3T3L1 adipocytes were plated in the lower wells, RAW264.7macrophages
were plated in the upper Transwell inserts containing a 0.4-m porous
membrane (Corning), and the cells were cultured overnight and then
used for the experiments.
Generation of primary mouse macrophages. To generate peritoneal
macrophages, PBS was injected into the peritoneal cavity. After massage
of the abdomen, the PBS was collected and then centrifuged at 1,000 rpm
for 5 min, and the cells were resuspended in RPMI supplemented with
10% FBS and antibiotics. Cells were plated at a density of 5 105 cells per
well of a 24-well dish. Themediumwas changed 24 h after plating, and the
macrophages were used for further studies.
Bone marrow-derived macrophages (BMDMs) were harvested from
the femur and tibia. The bones were first washed in 70% ethanol, and then
the bone marrow was flushed from the bone with DMEM supplemented
with 10% FBS. The bone marrow was resuspended into a single-cell sus-
pension, centrifuged for 5 min at 1,000 rpm, and then washed twice in
DMEM–10% FBS. Cells were then resuspended in DMEM supplemented
with 20% FBS and 30% L929 supernatant, plated at 107 cells per 10-cm
plate, and cultured for 3 days. After 3 days, fresh DMEM–20% FBS–30%
L929 was added to the cells. After 5 days, the plate was washed once with
PBS and the macrophages were used for further study.
Primary human macrophage differentiation. Primary human
monocytes were isolated by Ficoll gradient centrifugation and adhered to
6-well plates in RPMI 1640 medium supplemented with glutamine and
sodium pyruvate. After 1 h of incubation at 37°C, nonadherent cells were
removed by repeated washings. Adherent cells were incubated with mac-
rophage-specific medium (Invitrogen) containing glutamine, PEST and
granulocyte-macrophage colony-stimulating factor (GM-CSF; R&D Sys-
tems) for 3 days, after which the medium was replaced with fresh macro-
phage-specific serum-free medium (SFM) without GM-CSF. The cells
were then incubated for additional 3 days to generate well-differentiated
macrophages.
Inhibitors. JNK and IKK inhibitors were obtained fromEMD(catalog
no. 420119 and 401489). Cocultured 3T3L1 adipocytes and RAW264.7
macrophages were serum starved for 2 h, pretreated with 1 or 10Meach
inhibitor for 30min, and then incubatedwithRBP4 for 24 h before insulin
stimulation. For quantitative PCR analysis of cytokine expression in
Mechanism by Which RBP4 Causes Insulin Resistance
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RAW264.7 macrophages, these cells were pretreated with 1 M or 5 M
JNK inhibitor for 30 min and then incubated with RBP4 for the indicated
times.
Neutralizing antibodies. Neutralizing antibodies for tumor necrosis
factor alpha (TNF-), interleukin-6 (IL-6), and monocyte chemoattrac-
tant protein 1 (MCP-1) were obtained from R&D Systems (catalog no.
AB-410-NA, AB406-NA, andAB-479-NA). Cocultured 3T3L1 adipocytes
and RAW264.7 macrophages were serum starved for 2 h, pretreated with
1 g/ml or 5 g/ml of each neutralizing antibody or with combination of
5 g/ml of neutralizing antibodies for TNF-, IL-6, and MCP-1 for 30
min, and then incubated with RBP4 for 24 h before insulin stimulation.
Western blotting. Cells were lysed with 20 mM Tris-HCl (pH 7.5),
137 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 1% NP-40, 10% glycerol, 1
mM sodium orthovanadate, 5 mM NaF, 5 mM -glycerophosphate, and
protease inhibitor, including 1 mM phenylmethylsulfonyl fluoride
(PMSF) and 10 g/ml aprotinin. Lysates were subjected to immunoblot-
ting with the indicated antibody. The following antibodies from Cell Sig-
naling were used: Akt (catalog no. 9272), P-Akt Ser473 (catalog no. 9271),
P-Akt Thr308 (catalog no. 9275), IKK (catalog no. 2682), IKK (catalog
no. 2370), P-IKK/ (catalog no. 2078), JNK (catalog no. 9252), P-JNK
(catalog no. 9251), P-p38 (catalog no. 9211), p38 (catalog no. 9212), P-
ERK (catalog no. 9101), and ERK (catalog no. 9102).
Measurement of cytokine secretion. Cytokines (IL-2, IL-8, Il-12p70,
IL-1, GM-CSF, gamma interferon [IFN-], IL-6, IL-10, and TNF-)
secreted into conditioned medium from human macrophages were mea-
sured by a human proinflammatory 9-plex assay (Meso Scale Discovery).
In addition, MCP-1 secreted into conditioned medium was measured by
an enzyme-linked immunosorbent assay (ELISA) according to the man-
ufacturers’ instructions (Biosource).
The levels of secreted cytokines in culturemediumof RAW264.7mac-
rophages or mouse peritoneal macrophages were measured by ELISAs
from Biosource (TNF-, catalog no. KMC3011; IL-6, catalog no.
KMC0061; and MCP-1, catalog no. KMC1011).
Luciferase assay. The pNFB-Luc vector was purchased from Clon-
tech (catalog no. 631743). RAW264.7 macrophages were transfected with
the pNFB-Luc vector, alongwith a-galactosidase expression vector as a
control for transfection efficiency, using Fugene6 transfection reagent
from Roche (catalog no. 1815091). Luciferase activity in medium was
measured according to themanufacturer’s instructions andnormalized to
-galactosidase activity.
Generation of JNK1/ JNK2/ knockoutmacrophages.MaleC57
Mx1-Cre or C57 Mx1-Cre JNK1fl/fl JNK2/ mice (10) 4 weeks of age
were treated with 5 intraperitoneal injections of 20 g/g body weight
poly(I-C) over 5 to 7 days. Four weeks after treatment, bone marrow-
derived macrophages (BMDMs) were harvested and cultured. JNK1 de-
letion was confirmed by Western blotting. BMDMs were serum starved
for 2 h prior to treatment with 50 g/ml RBP4 for 24 h. The culture
medium was then collected, and the levels of secreted cytokines were
measured by ELISA.
Generation of TLR4/ macrophages. TLR4/ peritoneal macro-
phages were harvested as described above from male C57/Bl TLR4/
mice (JacksonLaboratory stock no. 007227; gift fromKatherine Fitzgerald
at the University of Massachusetts Medical School).
Human samples.All subjects included in this study were healthy non-
diabetic offspring of one parent with type 2 diabetes and one nondiabetic
parent, as determined by oral glucose tolerance test (OGTT) (6). Height
and weight were measured to the nearest centimeter and 0.1 kg, respec-
tively, and body mass index (BMI) was calculated as kg body weight di-
vided by height (m) squared. Fasting blood samples were drawn after an
overnight fast before an OGTT (75 g glucose) to evaluate glucose toler-
ance (6). Circulating glucose and insulin concentrations were determined
by standard laboratory methods. At 60 min after a glucose bolus, a eugly-
cemic-hyperinsulinemic clamp was initiated and carried out for the next
120 min (insulin infusion of 40 mUm2 min2) to evaluate insulin sen-
sitivity (6). Blood glucose was clamped at 5mmol/liter by infusion of 20%
glucose at various rates according to the blood glucose measurements
performed at 5-min intervals. The mean amount of glucose infused dur-
ing the last hour was used to calculate the rate of whole-body glucose
uptake. Lean bodymass was calculated frombioimpedance analysis (BIA-
101; Akern SRI, Florence, Italy).
Serum retinol andRBP4measurements. Serum retinol was extracted
as previously described (48) with minor modifications. Briefly, 50 l of
serum was mixed with 450 l of PBS, and 0.5 ml ethanol was spiked with
approximately 50 pmol of internal standard (IS) (2.5 l of 20 M retinyl
acetate in acetonitrile). Retinol was extracted twice in 2.5 ml hexane. The
organic solvent was evaporated under a stream of nitrogen, and retinol
extracts were resuspended in 50 l of acetonitrile.
Serum retinol and the internal standard were separated as previously
described (28). Briefly, we used reverse-phase chromatography (Zorbax
SB-C18, 2.1 by 50 mm, 1.8 m) under isocratic conditions (89% acetoni-
trile [ACN]–H2O–0.01% formic acid, 0.5 ml/min) on an Agilent 1100/
1200 high-performance liquid chromatograph. Retinol and retinyl acetate
were measured by UV absorbance at 325 nm and quantified using a stan-
dard curve. The injection volume was 10 l, and all samples were mea-
sured in duplicate. Retinol eluted at 1.14 min, and retinyl acetate (IS)
eluted at 1.94 min.
Total serum RBP4 was measured bymass spectrometry immunoassay
(MSIA) from 20 l of serum, as previously described (30, 64). Serum
retinol and RBP4 measurements were done in duplicate.
Quantitative PCR. An RNeasy kit (Qiagen) was used for RNA isola-
tion from human macrophages. Gene expression was analyzed with the
ABI Prism sequence detection system (TaqMan; Applied Biosystems).
Gene-specific primers and probes were designed using the Primer Express
software (Applied Biosystems) (see Table S1 in the supplemental mate-
rial). Each sample was run in duplicate, and the quantity of a particular
gene in each sample was normalized to ribosomal 18S RNA.
For studies of mouse macrophages, RNA was extracted using Tri-
Reagent (MRC, catalog no. TR 118) and cDNA was generated with ran-
dom hexamers (Clontech, catalog no. 639506). Quantitative real-time
PCR was performed with the ABI Prism sequence detection system. All
primers and probes used were obtained from Applied Biosystems, and
identification (ID) numbers for each gene are listed as follows: TNF-,
Mm00443258-m1; IL-6, Mm99999064-m1; MCP-1, Mm00441242-m1;
and GAPDH (glyceraldehyde-3phosphate dehydrogenase), 4352339E-
0902020. Expression levels of mRNA were normalized to those of
GAPDH.
RESULTS
RBP4 induces expressionof proinflammatory cytokines inmac-
rophages. We first examined whether RBP4 induces proinflam-
matory cytokines in macrophages. RAW264.7 macrophages (Fig.
1A) or primary mouse peritoneal macrophages (Fig. 1B) were
incubated with recombinant mouse holo-RBP4 (50 g/ml for 24
h) at a concentration present in serum of some insulin-resistant
humans (19, 31), and the levels of cytokines secreted into culture
medium were measured. RBP4 treatment markedly increased
TNF-, IL-6, and MCP-1 secretion in both types of macrophages
(Fig. 1A and B). Maximal effects were achieved with 50 g/ml
RBP4 (data not shown). The very low endotoxin concentration in
the incubation medium using this concentration of RBP4 was
tested as a separate control and showed no effects on cytokine
expression or secretion (data not shown).
Since retinol has many roles in cellular function, determina-
tion of whether the effect of RBP4 to induce cytokines is retinol
dependent is mechanistically important. To investigate this, we
incubatedmacrophages with eithermouse holo- or apo-RBP (Fig.
1C). As a control to ensure that the retinol-stripping process did
not damage the RBP4 protein, we also added back retinol to an
aliquot of apo-RBP4 (add-back RBP). The presence or absence of
Norseen et al.
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retinol in all forms of RBP4 was verified by fluorimetry (see Fig.
S1A in the supplemental material). We confirmed that apo-RBP4
remained free of retinol at the end of the incubation of the cells
with RBP4 by nondenaturing gel electrophoresis and Western
blotting (see Fig. S1B). Mouse holo-RBP4 increased the produc-
tion of TNF- and IL-6 by 3- to 5-fold and MCP-1 by nearly
2-fold. Surprisingly, mouse apo-RBP4 increased the secretion of
TNF- and MCP-1 by greater than 10-fold while increasing IL-6
secretion by greater than 100-fold (Fig. 1C). Apo-RBP4 with ret-
inol added back (add-back RBP4) had similar effects to the origi-
nal holo-RBP4, confirming that the retinol-stripping process used
to generate apo-RBP4 did not alter the function of the protein.
Wenext examinedwhether RBP4 induces cytokine production
in human macrophages and if this effect is retinol dependent.
Incubation of primary humanmacrophages with human holo- or
apo-RBP4 or add-backRBP4 (50g/ml for 24 h) strongly induced
secretion of TNF-, IL-6, and MCP-1 as well as the cytokines
IFN-, GM-CSF, IL-1, IL-2, IL-12p70, and IL-10 (Fig. 1D). IL-8
was the only cytokine we tested which was not induced by RBP4
treatment. To test whether increased cytokine secretion in re-
sponse to RBP4 reflects increased production, we measured ex-
pression of a subset of cytokines. In agreement with increased
cytokine secretion, both holo- and apo-RBP4 induced expression
of TNF-, IL-6, MCP-1, and IL-1 (Fig. 1E). Since peroxisome
proliferator-activated receptor  (PPAR) is a negative regulator
of proinflammatory pathways in macrophages (23), we also ex-
FIG 1 RBP4 induces cytokines inmouse and humanmacrophages. (A and B) Holo-RBP4 induces TNF-, IL-6, andMCP-1 secretion from cultured RAW264.7
macrophages (A) and primarymousemacrophages (B). (C)Mouse apo-RBP4 (Apo) has a greater effect than holo-RBP4 (Holo) on secretion of TNF-, IL-6, and
MCP-1 from RAW264.7 macrophages. Retinol was rebound to apo-RBP4 as an additional control (add-back). (D) Induction of cytokine secretion in primary
human macrophages after stimulation with human holo- or apo-RBP4 or add-back RBP4 relative to vehicle control. (E) Induction of TNF-, IL-6, MCP-1,
IL-1, and PPAR gene expression in primary humanmacrophages after treatment with holo- or apo-RBP4 or add-back RBP4 relative to the vehicle control. All
RBP4 incubationswerewith 50g/ml for 24 h. Either PBS or vehicle (dialysate)was used as a control. AU, arbitrary units. Data are expressed asmeans standard
errors (SE). For panels A and B, n	 3 per group; *, P
 0.05 versus vehicle by t test. For panel C, n	 3 per group; *, P
 0.05 versus vehicle; #, P
 0.05 versus
apo-RBP4 by ANOVA with post hoc analysis. For panels D and E, n	 7 per group. *, P
 0.05 versus vehicle by ANOVA with Wilcoxon analysis.
Mechanism by Which RBP4 Causes Insulin Resistance
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amined if PPAR expression is altered with RBP4 stimulation.
PPAR expression was decreased by 50 to 70% after treatment
with holo- or apo-RBP4 or add-back RBP4 (Fig. 1E). One inter-
pretation of these data is that reduced PPAR expression may be
involved in the induction of a proinflammatory state by RBP4.
These experiments were done under serum-free cell culture
conditions. Since serum is present in vivo, we repeated the exper-
iments in the presence of serum and obtained similar results (see
Fig. S1C in the supplemental material). Thus, the absence or pres-
ence of serum in the cell culture medium does not affect RBP4
stimulation of cytokine secretion from macrophages.
RBP4 inhibits insulin signaling in 3T3L1 adipocytes cocul-
tured with RAW264.7 macrophages. Macrophages can play a
critical role in the development of insulin resistance through in-
teracting with adipocytes (61, 63). We next tested whether RBP4
affects communication between adipocytes and macrophages. In
adipocytes cultured withoutmacrophages, RBP4 did not suppress
insulin-dependent AKT phosphorylation (Fig. 2A and B). In con-
trast, when 3T3L1 adipocytes were cocultured in a contact system
intermingled with macrophages, RBP4 treatment suppressed Akt
phosphorylation (S473 and T308) by 30 to 40% at both submaxi-
mal and maximal insulin concentrations (Fig. 2C and D). These
results suggest that macrophages are required for RBP4-mediated
inhibition of insulin-stimulated Akt phosphorylation in adi-
pocytes.
The signaling results in Fig. 2C and D are from the mixture of
adipocytes and macrophages, although the macrophages contrib-
ute relatively little to the total cellular protein. However, to defin-
itively show that the effect on Akt phosphorylation occurs in adi-
pocytes and not inmacrophages and that it results from a secreted
protein, we cocultured adipocytes withmacrophages in a noncon-
tact, Transwell system. RBP4 treatment suppressed insulin-de-
pendent Akt phosphorylation by 30% in adipocytes cocultured
with macrophages in the noncontact system, similar to the results
in the direct contact system, but not in adipocytes alone (Fig. 2E
and F). These results imply that macrophage-derived proinflam-
matory cytokines induced by RBP4 may mediate the impairment
in insulin signaling. To test this, we next investigated the effect of
neutralizing antibodies against proinflammatory cytokines on
RBP4-mediated inhibition of insulin signaling in adipocytes
cocultured withmacrophages. Pretreatment with neutralizing an-
tibodies for TNF-, IL-6, or MCP-1 (1 or 5 g/ml) for 30 min
prior to RBP4 treatment prevented RBP4-dependent inhibition of
insulin-stimulated Akt phosphorylation compared to the level
with control IgG (Fig. 2G and H). Each of these antibodies had a
significant effect, and treatment with all three neutralizing anti-
bodies completely reversed RBP4-dependent inhibition of insulin
FIG 2 RBP4 indirectly inhibits insulin signaling in adipocytes by stimulating
proinflammatory cytokine secretion from macrophages. (A) Representative
Western blot of total Akt and phosphorylated Akt (S473 and T308) in 3T3L1
adipocytes after direct treatment with holo-RBP4 (50 g/ml for 24 h) and
insulin stimulation (100 nM for 10 min). (B) Quantification of experiments
shown in panel A (n	 4). All conditions were normalized to cells treated with
PBS and stimulated with insulin. (C) Representative Western blot of total Akt
and phosphorylated Akt (S473 and T308) from contact coculture of 3T3L1
adipocytes and RAW264.7 macrophages after treatment with holo-RBP4 (50
g/ml for 24 h) and insulin stimulation (10 nM or 100 nM for 10 min). (D)
Quantification of experiments shown in panel C (n	 3). All conditions were
normalized to cells treated with PBS and stimulated with 10 nM insulin. *, P

0.05 versus vehicle under the same insulin conditions; #, P
 0.05 versus other
insulin conditions for no RBP4 by two-way analysis of variance (ANOVA)
with post hoc analysis. (E) Representative Western blot of total Akt and phos-
phorylated Akt (S473) from noncontact Transwell coculture of 3T3L1 adi-
pocytes and RAW264.7 macrophages after treatment with holo-RBP4 (50
g/ml for 24 h) and insulin (100 nM for 10 min). (F) Quantification of exper-
iments shown in panel E (n 	 4). All conditions were normalized to cells
treated with PBS and then stimulated with insulin. Macs, macrophages. *, P

0.05 versus no RBP4 in the absence or presence of macrophages; #, P 
 0.05
versus absence of macrophages with same RBP4 treatment by two-way
ANOVA with post hoc analysis. (G) Representative Western blot of total Akt
and phosphorylated Akt (S473) from contact coculture of 3T3L1 adipocytes
and RAW264.7 macrophages after treatment with neutralizing antibodies
(abs) (1 or 5g/ml as indicated) for 30 min prior to holo-RBP4 (50g/ml for
24 h) treatment and then insulin (100 nM for 10 min). (H) Quantification of
experiments shown in panel G (n	 2). All conditions were normalized to cells
treated with PBS and then stimulated with insulin. *, P
 0.05 versus no RBP4
with control IgG; #,P
 0.05 versus RBP4 treatmentwith control IgG.Data are
expressed as means SE except for panel H, in which n	 2.
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signaling (Fig. 2G and H). These findings indicate that RBP4 can
inhibit insulin signaling in adipocytes by inducing proinflamma-
tory cytokines in macrophages.
RBP4 activates signaling pathways in macrophages.Next we
sought to determine which pathways RBP4 activates in macro-
phages. We first tested the IB kinase (IKK)/NF-B pathway,
which plays a central role in cytokine production in macrophages
(57). RBP4 increased IKK/ phosphorylation in cultured mac-
rophages (Fig. 3A) and NF-B transcriptional activity, as deter-
mined by a 2-fold increase in NF-B luciferase activity (Fig. 3B).
Lipopolysaccharide (LPS) served as a positive control.
We next examined whether RBP4 activates other proinflam-
matory pathways. Both apo-RBP4 and holo-RBP4 treatment of
macrophages activated the JNK, p38, and ERK pathways, with a
peak effect at 30min (Fig. 3C). Similar to the results with cytokine
release in RAW264.7 macrophages (Fig. 1C), mouse apo-RBP4
had a much greater effect than holo-RBP4. In contrast, neither
apo-RBP4 nor holo-RBP4 activated the Akt pathway in macro-
phages (Fig. 3C). These results suggest that both holo- and apo-
RBP4 activate proinflammatory pathways at several steps.
RBP4 induces proinflammatory cytokines through the JNK
pathway in macrophages. We next sought to determine which
pathway is responsible for RBP4-mediated induction of proin-
flammatory cytokines in macrophages and for RBP4-mediated
inhibition of insulin signaling in adipocytes that are cocultured
with macrophages. IKK/NF-B and JNK play central roles in in-
flammatory pathways leading to insulin resistance (2, 7, 24). We
therefore tested the effect of specific inhibitors for JNK or IKK on
RBP4-mediated inhibition of insulin signaling in 3T3L1 adi-
pocytes cocultured with macrophages. Insulin-dependent Akt
phosphorylation was again inhibited by RBP4 treatment (Fig. 4A
and B). A JNK-specific inhibitor reversed this RBP4-dependent
inhibition of insulin signaling in a concentration-dependentman-
ner, while an IKK-specific inhibitor did not (Fig. 4A and B). The
JNK inhibitor also blocked RBP4-mediated induction of proin-
flammatory cytokines TNF-, IL-6, and MCP-1 in a concentra-
tion-dependent manner (Fig. 4C).
To further determine the role of JNK in RBP4 induction of
cytokines, we studied the effects in primary mouse macrophages
lacking JNK1 and JNK2. In control macrophages with functional
JNK1/2, holo-RBP4 stimulated IL-6, MCP-1, and TNF- secre-
tion and apo-RBP4 had a greater effect on IL-6 and MCP-1 (Fig.
4D), consistent with effects in cultured macrophages (Fig. 1C). In
the JNK1/ JNK2/ macrophages, the induction of IL-6 and
MCP-1 secretion by both holo- and apo-RBP4 was reduced by 35
to 75% relative to control macrophages, demonstrating a JNK-
dependent effect for both holo- and apo-RBP4. TNF- induction
was also retinol independent andwas independent of JNK in these
cells. Taken together, these results suggest that RBP4 inhibits in-
sulin signaling in adipocytes (Fig. 4A and B) by inducing proin-
flammatory cytokines in macrophages, in part through the JNK
pathway (Fig. 4C and D) and that this does not require that RBP4
be bound to retinol.
To understand whether this effect was mediated by STRA6
(stimulated by retinoic acid 6), the only known specific receptor
for RBP4 (5), we measured STRA6 expression by quantitative
PCR in all of the types ofmacrophages used in our studies.We did
not find expression of STRA6 in cultured or primary mouse mac-
rophages from either the peritoneum or the bone marrow from
several mouse strains (data not shown). Furthermore, we did not
detect STRA6 in cultured or primary human macrophages (data
not shown).
To determine whether another cell surface receptor could be
involved, we tested the role of the TLR4 receptor since phosphor-
ylation of JNK, ERK, and p38 and subsequent cytokine secretion
can be initiated by stimulation of TLR4 (21). A previous publica-
tion indicated that TLR4 was involved in cytokine secretion from
macrophages stimulated with holo-RBP4 (11). We sought to test
whether TLR4 is necessary for the effects of both holo- and apo-
RBP4 in primary macrophages (Fig. 4E). In wild-type primary
mouse macrophages, holo- and apo-RBP4 and add-back RBP4
stimulate IL-6 and TNF- secretion. However, in TLR4/mac-
rophages, IL-6 and TNF- secretion is attenuated by 60 to 80%
(Fig. 4E). The partial suppression of IL-6 secretion in TLR4/
macrophages is similar to that seen in the JNK1/ JNK2/mac-
rophages. In contrast, TNF- secretion is also attenuated in the
TLR4/macrophages but not in the JNK1/ JNK2/macro-
phages, suggesting that another pathway downstream of TLR4
may also be involved.
The RBP4/retinol ratio is elevated in insulin-resistant hu-
mans independent of obesity. Since the cytokine-induced im-
pairment of insulin signaling by RBP4 is retinol independent, we
wanted to know the potential physiological significance of apo-
RBP4. Apo-RBP4 has been shown to be elevated in humans with
FIG 3 RBP4 activates proinflammatory signaling pathways in macrophages.
(A) Western blot of total and phosphorylated IKK/IKK from RAW264.7
macrophages treated with holo-RBP4 (50 g/ml) for the indicated times. (B)
Quantification of NF-B promoter activity in RAW264.7 macrophages trans-
fectedwith pNFB-Luc reporter plasmid and then treatedwith holo-RBP4 (50
g/ml for 18 h). LPS (10 ng/ml) was used as a positive control. AU, arbitrary
units. Data are expressed as the mean SE and normalized to -galactosidase
(-Gal) expression. *, P 
 0.05 versus PBS. (C) Western blot of total and
phosphorylated Akt, ERK, p38, and JNK from RAW264.7 cells that were
treated with either apo- or holo-RBP4 (50 g/ml) for the indicated times.
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obesity, type 2 diabetes, and/or renal failure (12, 13, 39). To de-
termine whether apo-RBP4 is elevated in association with obesity
per se or in insulin-resistant states regardless of BMI, wemeasured
the ratio of apo- to holo-RBP4 in insulin-sensitive and insulin-
resistant lean humans and in insulin-resistant obese subjects. The
lean insulin-resistant and obese insulin-resistant subjects were
matched for equivalent levels of insulin resistance, as determined
by the glucose disposal rate during a euglycemic-hyperinsuline-
mic clamp (Table 1).
Our data show that total RBP4 levels are increased by 2.5- to
3-fold in both lean and obese insulin-resistant subjects (Fig. 5A).
The magnitudes of elevation in lean and obese insulin-resistant
subjects are similar. While total serum retinol levels do not vary
significantly between insulin-sensitive and insulin-resistant lean
subjects, retinol is slightly elevated in obese subjects relative to the
level in the lean groups combined (Fig. 5B). We calculated the
molar ratio of total RBP4 to total retinol and found that the ratios
were equivalently elevated in lean and obese insulin-resistant sub-
jects (Fig. 5C). This demonstrates that apo-RBP4 relative to holo-
RBP4 is increased in the setting of insulin resistance even in lean
subjects and that it does not require obesity for this elevation to
occur. Infusion of insulin and glucose (euglycemic clamp) did not
alter RBP4, retinol, or RBP4/retinol ratio in any group.
DISCUSSION
Mounting evidence indicates that stimulation of proinflamma-
torymacrophages is a critical component formaintaining chronic
inflammation in adipose tissue in the setting of obesity-induced
insulin resistance (42, 55, 62, 63). However, there is debate over
what factors establish and maintain this inflammation. Our study
provides evidence that the elevated RBP4 levels associated with
insulin resistance and obesity (19, 31, 47, 65) may contribute to
either initiating or sustaining this proinflammatory state by acti-
vating macrophages. Through this mechanism, RBP4 indirectly
FIG 4 JNK and TLR4 at least partiallymediate the effects of RBP4 on insulin stimulation and cytokine production. (A)Western blot of total and phosphorylated
Akt in 3T3L1 adipocytes from direct contact coculture with RAW264.7 macrophages. Cells were pretreated with JNK or IKK inhibitor (1 or 10 M for 30 min),
and then human holo-RBP4 was added (50 g/ml for 24 h) prior to insulin (100 nM for 10 min). (B) Quantification of experiments shown in panel A. All
conditions were normalized to cells treated with PBS and then stimulated with insulin. Data are means SE. *, P
 0.05 versus insulin-stimulated () with no
RBP4. (C)mRNAexpression of TNF-, IL-6, andMCP-1 inRAW264.7macrophages treatedwith JNK inhibitor (1 or 5M) andRBP4 as in panel A. The control
for RBP4was dialysate, and the control for JNK inhibitor was dimethyl sulfoxide (DMSO). AU, arbitrary units. Data aremeans SE and normalized to GAPDH
expression (n	 3 to 4). *, P
 0.05 versus no RBP4; #, P
 0.05 versus no JNK inhibitor;, P
 0.05 versus RBP4 plus 1 M JNK inhibitor, one-way ANOVA.
In, inhibitor. (D) TNF-, IL-6, andMCP-1 secretion from primarymousemacrophages stimulated with holo- or apo-RBP4 or add-back RBP4 (50g/ml for 24
h).Macrophages were harvested from either control mice with functional JNK1 and JNK2 ormice with JNK1 and JNK2 deleted (JNK1/2 KO). Data aremeans
SE (n	 4). *, P
 0.05 versus vehicle (dialysate) treatment within the same genotype; #, P
 0.05 for JNK1/2 KO versus control with same treatment;, P
 0.05
versus holo-RBP4 and add-back RBP4 treatment within same genotype by two-way ANOVAwith post hoc analysis. (E) TNF- and IL-6 secretion from primary
mousemacrophages stimulatedwith human holo- or apo-RBP4 or add-back RBP4 (50g/ml for 24 h).Macrophages were harvested and pooled from either two
wild-type mice (open circles) or two mice with TLR4 deleted (TLR4 KO) (closed circles), and the experiments were done in duplicate. The bars show the mean
with individual values indicated by circles (n	 2). *, P
 0.05 versus vehicle (dialysate) treatment within the same genotype; #, P
 0.05 for TLR4 KO versus
control with same treatment;, P
 0.05 versus holo- and add-back RBP4 treatment within same genotype by two-way ANOVA with post hoc analysis.
TABLE 1 Anthropometric and metabolic characteristics of human
subjects included in Fig. 5
Characteristic
Result for groupa:
Lean insulin
sensitive
Lean insulin
resistant
Obese insulin
resistant
Gender (no. male/female) 4/4 4/4 4/4
Age (yr) 42.2 2.4 36.6 2.3 39.0 2.6
BMI (kg/m2) 22.3 0.5 22.3 0.5 31.1 0.3
GIR (mg/kg LBMmin)b 19.3 0.7 8.19 0.5 8.09 0.8
HbA1c (%) 4.14 0.07 4.18 0.05 4.09 0.12
a All subjects were nondiabetic. Except for gender, data are expressed as means SE.
n	 8 per group.
b The glucose infusion rate (GIR) was determined by euglycemic-hyperinsulinemic
clamp as described previously (6). Lean body mass (LBM) was determined by
bioimpedance analysis.
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impairs insulin action in adipocytes. Furthermore, this effect of
RBP4 is mediated, in part, through the JNK and TLR4 pathways
and is independent of retinol binding to RBP4.
We show that RBP4 induces expression and secretion of pro-
inflammatory cytokines in primary humanmacrophages aswell as
in mouse macrophages. The robust RBP4-stimulated cytokine re-
sponse in primary human cells results in production ofmany pro-
inflammatory cytokines, including TNF-, IL-6, MCP-1, IFN-,
GM-CSF, IL-1, IL-2, and IL-12p70. The concomitant decrease in
PPAR, a negative regulator of inflammation, indicates that re-
duction in PPAR could be part of the mechanism for the proin-
flammatory effects of RBP4. Similar to the effects in obesity,
whereby localized adipose tissue inflammation promotes insulin
resistance (42), we find that RBP4-induced cytokine production
from macrophages causes insulin resistance in adipocytes, and
this is blocked by neutralizing antibodies for several cytokines.We
also find that RBP4 strongly induces IL-10, which is typically con-
sidered an anti-inflammatory cytokine. This may be a compensa-
tory response to the proinflammatory signals since the simultane-
ous induction of pro- and anti-inflammatory cytokines also
occurs in the inflammation induced by a high-fat diet (14).
Multiple redundant and overlapping signaling pathways me-
diate proinflammatory effects in cells (21, 42).We show that RBP4
activates the p38, ERK, NF-B, and JNK signaling pathways in
macrophages. In our studies, blocking of JNK signaling caused the
greatest decrease in RBP4-stimulated cytokine secretion and in
the resulting insulin resistance in adipocytes. The reduced effect of
RBP4 on stimulation of IL-6 and MCP-1 in JNK1/ JNK2/
macrophages strongly supports a critical role for JNK in RBP4-
induced inflammation. The persistent effect on TNF- produc-
tion in these macrophages is not surprising because TNF- pro-
duction is stimulated by multiple signaling pathways, but IL-6
production is more indicative of JNK activation (59).
A recent report indicated that holo-RBP4 induces TNF- and
IL-6 through a TLR4-dependent pathway (11). We show that
TLR4 is necessary for complete stimulation of cytokine release
from macrophages treated with either holo- or apo-RBP4. The
fact that RBP4-induced TNF- secretion is attenuated in
TLR4/ macrophages but not in JNK1/ JNK2/ macro-
phages indicates another pathway downstream of TLR4 may be
involved in the RBP4 effects. The fact that the RBP4 effects are not
completely blocked in TLR4/macrophages suggests that addi-
tional parallel pathways may be involved.
Since RBP4’smost well-defined function is to deliver retinol to
tissues and retinol has many important effects on the immune
system, it would not have been surprising if the action of RBP4 on
adipose tissue inflammation was retinol dependent. However, we
find that apo-RBP4 elicits a cytokine response as robust as that of
holo-RBP4 in macrophages. While we observe a 10- to 100-fold-
enhanced effect of mouse apo-RBP4 in the mouse macrophage
cell line, RAW264.7, (Fig. 1C and 3C), we do not observe this with
human apo-RBP4 in the same cell line or in primary humanmac-
rophages (Fig. 1D). The effect of human apo-RBP4 in primary
mouse macrophages is only about 50 to 80% greater than that of
holo-RBP4 (Fig. 4D and E). The reason for the differential effects
ofmouse RBP4 and humanRBP4 is not known, but the important
conclusion is that RBP4 can elicit cytokine secretion frommacro-
phages in a retinol-independent manner.
Our data show an increase in serum apo-RBP4 (Fig. 5C) in
both lean and obese insulin-resistant subjects. This implies that
elevation of RBP4, and not a concordant increase in retinol, is
associated with insulin resistance. It is not obesity per se that is
associated with increased apo-RBP4 but rather insulin resistance.
Interestingly, glucose-insulin infusion did not alter the levels of
retinol, RBP4, or the RBP4/retinol ratio in lean or obese subjects,
underscoring the relative stability of these levels.
The data in this paper demonstrate a novel alternative mecha-
nism for RBP4 action and demonstrate that the RBP4 protein
directly induces proinflammatory signaling pathways indepen-
dent of retinol. Furthermore, we find that the effects of RBP4 to
impair insulin signaling in adipocytes are indirect since they re-
quire the presence of macrophages (Fig. 2A to F). In contrast, a
recent study reported that RBP4 inhibits insulin signaling directly
in adipocytes by activating JAK2/STAT5 signaling, which induced
SOCS3 expression (4). This mechanism is retinol-dependent and
requires themembrane protein STRA6. The proinflammatory ac-
tions of RBP4 in macrophages are not STRA6 dependent since we
did not detect STRA6 expression in any of the macrophages used
in our studies. A STRA6-independent effect is not surprising since
overall, the role of STRA6 in RBP4 actions and retinoid biology is
FIG 5 The ratio of apo-RBP4 to holo-RBP4 is elevated in human subjects with insulin resistance but not altered by insulin-glucose infusion during a
euglycemic-hyperinsulinemic clamp. Values in serum from lean insulin-sensitive (I.S.), lean insulin-resistant (I.R.), and obese insulin-resistant nondiabetic
subjects before (closed circles) and after (open circles) euglycemic-hyperinsulinemic clamp are shown. RBP4 levels (g/ml)weremeasured bymass spectrometry
immunoassay (A), and total serum retinol (M) was measured by HPLC (B). (C) The molar concentration of serum RBP4 and retinol was used to calculate the
molar ratio of RBP4 to retinol in serum for each subject. Data are means  SE, with individual values shown (n 	 8 per group). *, P 
 0.05 versus lean
insulin-sensitive subjects both before and after euglycemic-hyperinsulinemic clamp, as determined by two-way ANOVA with post hoc analysis. #, P
 0.05 for
retinol values in obese subjects versus the two lean groups combined. The lean groups were combined because there was no difference in retinol values between
the lean groups. The retinol values for each subject before and after clamp were averaged for comparison of obese versus lean serum retinol values by t test.
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controversial (5). The results presented here do not contradict the
findings of Berry et al. (4) since the effects of the JAK/STAT path-
way in adipocytes may be retinol and STRA6 dependent, whereas
the effects of RBP4 on cytokine production in macrophages are
not. Differences in RBP4 signaling in adipocytes andmacrophages
are also indicated by our finding that RBP4 increases ERK activa-
tion inmacrophages, in contrast to a previous report showing that
RBP4 impairs insulin-stimulated ERK signaling in adipocytes
(43). Importantly, both direct and indirect effects of RBP4 on
adipocyte insulin signaling may contribute to insulin resistance.
In conclusion, we have identified a novel mechanism for RBP4
action that does not require either retinol or STRA6.We show that
RBP4 induces a proinflammatory response in macrophages
through JNK- and TLR4-dependent pathways, and the resulting
cytokine production causes insulin resistance in adipocytes. These
findings provide insights into the cellular mechanisms by which
RBP4 causes insulin resistance and could lead to new therapeutic
approaches to reduce obesity-related inflammation and insulin
resistance.
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